{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:41:19Z","timestamp":1774672879138,"version":"3.50.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>For extended-release drug formulations, effective half-life (t<jats:sub>1\/2eff<\/jats:sub>) is a relevant pharmacokinetic parameter to inform dosing strategies and time to reach steady state. Tacrolimus, an immunosuppressant commonly used for the prophylaxis of organ rejection in transplant patients, is available as both immediate- and extended-release formulations. To the best of our knowledge, the t<jats:sub>1\/2eff<\/jats:sub> of tacrolimus from these different formulations has not yet been assessed. The objective of this study was to characterize the t<jats:sub>1\/2eff<\/jats:sub> and terminal half-life (t<jats:sub>1\/2z<\/jats:sub>) of an extended-release once-daily tacrolimus formulation (LCPT) and twice-daily immediate-release tacrolimus (IR-Tac).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A noncompartmental analysis of pharmacokinetic data obtained from a phase 2 study in de novo kidney transplant recipients receiving either LCPT or IR-Tac was conducted. Intensive blood sampling was performed on days 1, 7, and 14, and tacrolimus whole blood concentrations were measured using a validated liquid chromatography with tandem mass spectrometry method. T<jats:sub>1\/2eff<\/jats:sub> was estimated using within-participant accumulation ratios. T<jats:sub>1\/2z<\/jats:sub> was estimated by linear regression of the terminal phase of the concentration versus time profile.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The median accumulation ratios of LCPT and IR-Tac on day 14 were 3.18 and 2.06, respectively.<\/jats:p>\n            <jats:p>The median (interquartile range; IQR) t<jats:sub>1\/2eff<\/jats:sub> for LCPT at day 14 of dosing was 48.4 (37.4\u201377.9) hours, whereas the t<jats:sub>1\/2z<\/jats:sub> was 20.3 (17.6\u201322.9) hours. For IR-Tac, the median (IQR) t<jats:sub>1\/2eff<\/jats:sub> and t<jats:sub>1\/2z<\/jats:sub> on day 14 were 12.5 (8.8\u201323.0) hours and 12.2 (9.2\u201315.7) hours, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Consistent with its prolonged release of tacrolimus, LCPT demonstrated a higher accumulation ratio and a longer t<jats:sub>1\/2eff<\/jats:sub> compared with IR-Tac. These findings underscore the pharmacokinetic differences between different drug formulations of the same moiety and may help inform dose adjustments for LCPT in kidney transplantation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001270","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T18:01:14Z","timestamp":1729792874000},"page":"169-173","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients"],"prefix":"10.1097","volume":"47","author":[{"given":"Jeremiah D.","family":"Momper","sequence":"first","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raman","family":"Venkataramanan","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arin S.","family":"Jantz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Henry Ford Health, Detroit, Michigan ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane M.","family":"Cibrik","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Kansas Health System, Kansas City, Kansas ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Birdwell","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee ; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tk","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1841-5135","authenticated-orcid":false,"given":"Brian M.","family":"Masters","sequence":"additional","affiliation":[{"name":"Medical Affairs, Veloxis Pharmaceuticals, Inc., Cary, North Carolina ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir J.","family":"Patel","sequence":"additional","affiliation":[{"name":"Medical Affairs, Veloxis Pharmaceuticals, Inc., Cary, North Carolina ."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"R1-20250108","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eplepsyres.2016.10.020","article-title":"The application of half-life in clinical decision making: comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate","volume":"129","author":"Gidal","year":"2017","journal-title":"Epilepsy Res."},{"key":"R2-20250108","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s11095-008-9787-9","article-title":"The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms","volume":"25","author":"Sahin","year":"2008","journal-title":"Pharm Res."},{"key":"R3-20250108","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00044011-200626120-00002","article-title":"Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug: as shown by once-daily divalproex-ER","volume":"26","author":"Dutta","year":"2006","journal-title":"Clin Drug Investig."},{"key":"R4-20250108","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/j.1552-4604.1995.tb04117.x","article-title":"Effective half-life in clinical pharmacology","volume":"35","author":"Boxenbaum","year":"1995","journal-title":"J Clin Pharmacol."},{"key":"R5-20250108","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","article-title":"Pharmacokinetics and drug interactions of eslicarbazepine acetate","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"R7-20250108","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/TP.0b013e3182962cc1","article-title":"Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients","volume":"96","author":"Gaber","year":"2013","journal-title":"Transplantation"},{"issue":"suppl 5","key":"R8-20250108","first-page":"335","article-title":"Improved bioavailability of MELTDOSE once-daily formulation of tacrolimus (LCP-Tacro) with controlled agglomeration allows for consistent absorption over 24 hrs: a scintigraphic and pharmacokinetic evaluation [abstract]","volume":"13","author":"Nigro","year":"2013","journal-title":"Am J Transpl."},{"key":"R9-20250108","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/ajt.13935","article-title":"A steady-state head-to-head pharmacokinetic comparison of all FK-506 (tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period crossover study","volume":"17","author":"Tremblay","year":"2017","journal-title":"Am J Transpl."},{"key":"R10-20250108","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/FTD.0000000000000773","article-title":"Chronopharmacokinetics and food effects of single-dose LCP-tacrolimus in healthy volunteers","volume":"42","author":"Alloway","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R11-20250108","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/17425255.2017.1395413","article-title":"Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients","volume":"13","author":"Andrews","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R13-20250108","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","article-title":"Clinical pharmacokinetics of tacrolimus","volume":"29","author":"Venkataramanan","year":"1995","journal-title":"Clin Pharmacokinet."},{"key":"R14-20250108","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet."},{"key":"R15-20250108","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.ajkd.2017.07.018","article-title":"Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate-release versus extended-release tacrolimus in African American kidney transplant recipients","volume":"71","author":"Trofe-Clark","year":"2018","journal-title":"Am J Kidney Dis."},{"key":"R16-20250108","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/FPC.0000000000000494","article-title":"Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation","volume":"33","author":"Rao","year":"2023","journal-title":"Pharmacogenet Genomics"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:00:56Z","timestamp":1736348456000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001270","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]}}}